George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Agree. Seemed like fake drop to fill the Buy order.
Looking forward to positive Updates next week due on Multiple fronts.
Bigeasy.
Very nicely summarised. Spot on. You nailed it.
I myself used to support Stock borrow / lending trading desk in my earlier career and know how these sharks work. Unfortunately management of Pharma / Biotech companies fall for their glittery deal structures. Rest of the game you know.
May be James Cheek (CEO) reads GDR chat board and finally got the true picture.
Some good posts. Just catching up here. Staying put here as this will come good. Been frustrating yes, but GDR could prove to be one of the best turnaround / recovery stock for 2024 regaining its past glory.
From last RNS, i get a feeling Management has realised now that RF finance deal was a bad choice and could soon be cancelling that and replace with a standard placing deal to get rid of current RF deal. Interesting to note that RF warrants Exercise price is upwards of +10p.
Even the slightest sniff of RF deal cancelled...and there will be major fireworks in share price rocket 🚀 upwards as market just want RF out.
Followed by RNS updates on NICE and FDA in USA. Then we would be back on track to massive price gains. Almost there now in my view.
London price was trading circa 40% below ASX price in Australia.
ASX closed at 2.10 cents on double the daily average traded volume.
London price should be around 1.20 - 1.25
Still trading at a discount to ASX price.
I expect ASX to continue rising especially after superb initial results from ARV 100% owned Mt Marie licence which confirm Spodumene lithium source and at par with same grades to next door Azure Minerals currently subject to A$1.76bn take over offer price.
Wont be surprised if this hit over +2p in coming days and still would be mega cheap.
Some bio-tech firms take years to develop a breakthrough, market disruptive product.
Genedrive....very apt name coz genes driven therapy and testing is the future.
BIG PHARMA know it and would swallow any small bio-tech with those intellectual rights to such products.
James Cheek had to deal with a lot since coming on board...fully focused on progressing product sales for AIHL test to establish a revenue stream. Stroke tests would be next with lot of progress already made.
Pharmacogenetics market expected to hit $40bn by 2033. Genedrive can capture a good chunk of that in Worldwide sales in coming years.
Price would be in multiple £££s...not pennies if you stay here in next 5-10 years. GeneDrive would be a different fish altogether.
IMHO. DYOR
Some great posts..Stephen, Jimi and Lionel.
We on the cusp of doing +100% plus on next positive news.
We could get back to back RNS on multiple fronts and this could do even 200%-300%.
Shorters know it and seem worried as we could get a big short squeeze knowing how fast this moves.
Guy...not really. Think you got it wrong.
Product sale price will most likely be in local currency of the country.
E.g. you can buy same iphone in UK, Europe and USA but priced very differently.
"this level of li2o result is unparalleled in the region and is on par with the results achieved at the andover project of azure minerals ltd where they recorded a peak rock chip assay result of 4.87% li2o3 and have reported an exploration target of 100-240mt @ 1.00-1.5% li2o4 (azure minerals is currently subject to a takeover proposal via a joint bid from sociedad quimica y minera de chile sa (sqm) and han**** prospecting pty ltd)."
azure currently under a$1.76 billion buy out offer.
mt marie - looking better and better than expected. artemis sitting on something special. current mcap only a$30m ?
Guy
No pump n dump here sir. I am taking advantage of this low price to accumulate few more wherever i can to build a decent size position.
Cannot speak for others. Each to their own.
But can see fair few investors starting to take positions here for March updates on "Multiple" fronts. Could get back to back RNS.
52 week high....48.86 pence.
Adjusted for dilution, with positive news on different fronts, this can rocket to +40p in no time.
At only 5p this is defo a STRONG BUY in my books.
The Pharmacogenomics Market size is estimated at USD 8.67 billion in 2024, and is expected to reach USD 11.67 billion by 2029, growing at a CAGR of 6.12% during the forecast period (2024-2029).
Pharmacogenetic testing may be used to: Find out whether a certain medicine could be effective for you. Find out how much of the medicine you need. Predict whether you will have a serious side effect from a medicine.
Some folks keep banging on about funding. We already got funding mechanism in place albiet not the best option chosen by them at the time.
Best option would have been issuing say 50m shares around 20p when we touched 43p. Since then it has fallen to 5p.
Having said that we can also have incoming partner injecting Investment Capital in return for future Royalties from sales enabling GDR to cancel current Riverfort finance deal.
You could then see a Massive jump in price towards 35p - 40p range in Double quick time.
Full NHS rollout should also bring in strong revenue from UK alone. Then add revenues from Europe and Middle East. So i see MASSIVE Upside and ROI from 5p.
CEO James Cheek previous roles and contacts at ROCHE, CEPHID, Beckman Coulter (Danaher Corp) should bring collaboration/ partner deals in near term.
Revenues should soon kick in from Distribution deals across Europe & Middle East. Additional Revenues from NHS roll out also.
See no reason why we cannot revisit +43p or higher touched in March 2023. We are lot more advanced now than 1 year ago. Current funding deal in place could be terminated immediately soon as Revenues start coming in OR incoming Partner injects Investment Capital in return for Royalties.
Incoming FDA partner providing funding for a slice of Royalties would be a very smart move in my view and very strong possibility going down this route. Win / Win for all parties.
Genedrive gaining lot of attention in USA. Any NASDAQ listed bio-tech could be one of the interested parties. Will find out soon.
Genedrive defo getting attention and coverage across Middle East, Europe and USA.
Positive news due on "Multiple" fronts.
Sales distribution partnership Deal(s).
FDA partner update (USA)
NICE recommendation & NHS roll out (UK)
AIHL and STROKE tests - updates
Target market Worldwide worth Billions $$$
GDR on watchlist of many and is one of those stocks that can jump from 5p to 50p real fast.
Lionel.
That is an excellent article highlighting pharmacogenetics as the future. Quote below:
"This represents a new paradigm in healthcare, moving away from the established one-size-fits-all approach to a more precise, bespoke prescribing strategy based on a person’s individual genetic profile."
Both AIHL and Stroke tests developed by Genedrive Plc are going to be game changer for the Healthcare Industry globally target a market worth $$$ Billions worldwide.
Jimi.
That is very good article. Genedrive getting lot of exposure in USA.
FDA news not far now. MMs trying to collect few on the cheap ahead of news.
We must also be close on partnership deals in both Europe and The Middle East.
Plus the £10m Govt backed funding deal.
Updates on Stroke tests also to look forward to.
Current MCap of £6m only is at rock bottom. News expected on "Multiple" fronts. This can easily rocket to £60m - £75m MCap in a heartbeat on positive update.
US partner deal cannot be far now.
Add on top of that - UAE (Dubai & Abu Dhabi) , Qatar and wider Middle-East product marketing & distribution deals.
Managed to get some now after few attempts.
Current MCap of only £7m is so ridiculous.
NHS contracts alone could be 10 x times that.
Cannot buy more than £100 worth ??
What is going on here !!! About to move higher.
Ridiculously cheap with news about to land.